Key Insights on Lecanemab and Alzheimer’s Care

The Alzheimer’s Treatment Briefing

Coverage period: October 28–November 3, 2025 (U.S.)

Note up front: It’s been another light week for headline approvals or Phase 3 readouts. Still, a few items meaningfully add to what clinicians and families should know now.

Top stories (ranked)

  1. Real‑world clinic experience with lecanemab clarifies who is at higher risk for side effects
  • What’s new
    • A large specialty memory clinic reported outcomes from 234 patients started on lecanemab over 14 months. About 1 in 5 developed ARIA (MRI changes like swelling or small bleeds), mostly mild and without symptoms. Crucially, people who started treatment at the “mild dementia” stage had far more symptomatic ARIA than those treated earlier at the MCI/very‑mild stage (27% vs 1.8%). That reinforces the “earlier is better” message for both benefit and safety. (jamanetwork.com)
  • Why this matters
    • This is practical, real‑world evidence (not just a trial). It supports starting therapy earlier in the disease course when appropriate, and it can guide MRI monitoring and counseling about risk. It also aligns with FDA’s safety advice to add an early MRI before the 3rd infusion to catch ARIA sooner. (fda.gov)
  1. Medicare’s 2026 physician fee rule finalizes “virtual supervision,” which could ease treatment bottlenecks
  • What’s new
    • CMS’ final 2026 Physician Fee Schedule (released Oct 31) permanently allows “direct supervision” via real‑time audio/video. In plain terms, certain services can be overseen remotely. CMS also updates practice‑expense methodology, which can shift payments for office‑based services. Details vary by code, but together these changes may help clinics flex staffing (for infusions, MRI monitoring logistics, and patient education) as demand grows in 2026. (aha.org)
  • Why this matters
    • Access to antibody therapy depends on clinic capacity (infusions, MRIs, safety checks). Remote supervision options can widen coverage in understaffed settings and rural areas, potentially shortening wait times. Practices should review local MAC guidance and specific codes to see how reimbursement and workflows are affected. (aha.org)
  1. Countdown to CTAD (Dec 1–4, San Diego): final program locked, no onsite registration
  • What’s new
    • CTAD confirmed its final program and logistics. Expect late‑breaking treatment and monitoring data (including non‑antibody approaches and digital/biomarker tools). With no onsite registration, planning is set—and so is the timing for when major updates will land. (ctad-alzheimer.com)
  • Why this matters
    • If you’re considering starting or switching therapy in November, it may be worth timing decisions with early‑December data drops that could affect regimen choice, monitoring intensity, or patient selection. (ctad-alzheimer.com)

What this means in plain language

  • Starting disease‑slowing treatment earlier tends to be safer and more effective than waiting until symptoms are more advanced. New clinic data back this up and support earlier MRI checks to spot side effects before they cause problems. (jamanetwork.com)
  • Medicare’s new 2026 rules could make it easier for clinics to supervise parts of care remotely. That may expand access next year, especially where staffing is tight. Check with your clinic on how this will change scheduling and monitoring in your area. (aha.org)
  • The next wave of treatment‑shaping results arrives at CTAD, December 1–4. Plan around that timing if possible. (ctad-alzheimer.com)

Quick guidance for patients and caregivers this week

  • Ask about “stage and safety”: If you or a loved one are at the borderline between MCI and mild dementia, ask your clinician how stage affects both expected benefit and side‑effect risk, and whether an earlier MRI (before infusion #3) is part of their protocol. (jamanetwork.com)
  • Clarify November–December timing: If a treatment decision is imminent, ask whether any CTAD readouts in early December could change your plan. (ctad-alzheimer.com)
  • For 2026 planning: Clinics should review the finalized Medicare rule to see how virtual supervision and expense updates might expand capacity and reduce delays for infusions and MRI monitoring. Patients can ask if their site expects shorter waits in early 2026. (aha.org)

If you’d like, I can monitor CTAD sessions live December 1–4 and deliver a same‑day, plain‑English digest focused strictly on treatment takeaways.